Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for non-small cell lung cancer. The FDA has accepted ...
On the 5th, HLB PANAGENE said that the "PANAMutyper™ ROS1" has received item approval from the Ministry of Food and Drug Safety as a companion diagnostic product for Pfizer's lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback